Meeting
2017 ASCO Annual Meeting
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
Authors
Yingmiao Liu
Duke University Medical Center, Durham, NC
Yingmiao Liu , Zhenhua Yuan , Dadong Zhang , Mark D. Starr , John C. Brady , Manoj A. Jivani , Bonne J. Adams , Delia Alvarez , Steven Attia , Toni K. Choueiri , Charles P. Theuer , Kouros Owzar , Herbert Hurwitz , Andrew B. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11546)
DOI
10.1200/JCO.2017.35.15_suppl.11546
Abstract #
11546
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
First Author: Tanya B. Dorff
Poster
2015 Genitourinary Cancers Symposium
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
First Author: Toni K. Choueiri
Poster
2014 ASCO Annual Meeting
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
First Author: Yingmiao Liu
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
First Author: Andrew Warren Hahn